STOCK TITAN

AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences
Rhea-AI Summary
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced that CEO Jim Corbett will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company focuses on regenerative medicine for skin restoration and will provide a live audio webcast of the presentation on their website.
Positive
  • None.
Negative
  • None.

VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 11:15 a.m. Pacific Time.

A live audio webcast of the presentation will be available under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com. A replay of the webcast will be available at the same location for approximately 30 days following the conclusion of the event.

About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care for skin restoration with innovative devices and autologous cellular therapies. At the forefront of our platform is the RECELL® System, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin Cells, delivering a transformative solution at the point-of-care. RECELL enables improved clinical outcomes. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

 


FAQ

What is the date of the 42nd Annual J.P. Morgan Healthcare Conference presentation by AVITA Medical, Inc.?

The presentation will take place on January 11, 2024.

What time will CEO Jim Corbett present at the conference?

The presentation is scheduled for 11:15 a.m. Pacific Time.

Where can I access the live audio webcast of the presentation?

The live audio webcast will be available on AVITA Medical's website at https://ir.avitamedical.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available at the same location for approximately 30 days following the conclusion of the event.

Avita Medical, Inc.

NASDAQ:RCEL

RCEL Rankings

RCEL Latest News

RCEL Stock Data

231.17M
24.81M
0.66%
28.08%
2.83%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
VALENCIA

About RCEL

avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.